Business Segments · Antitrust legal settlements
North American Pharmaceutical — Antitrust legal settlements
This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ3 2024
Last reportedQ4 2025
How to read this metric
An increase represents higher legal risk and potential negative impact on segment margins, while a decrease suggests a reduction in litigation-related liabilities.
Detailed definition
This metric tracks the financial impact of legal settlements specifically related to antitrust litigation within the Nor...
Peer comparison
Commonly reported by major pharmaceutical wholesalers who face systemic industry litigation, comparable to peers in the 'Big Three' wholesalers.
Metric ID:
mck_segment_north_american_pharmaceutical_antitrust_legal_settlementsHistorical Data
4 periods
| Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|
| Value | $63.00M | $31.00M | $0.00 | $15.00M |
| QoQ Change | — | -50.8% | -100.0% | — |
| YoY Change | — | — | -100.0% | -51.6% |
Range$0.00 – $63.00M
Avg YoY Growth-75.8%
Median YoY Growth-75.8%
Current Streak3+ quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's north american pharmaceutical — antitrust legal settlements?
- McKesson (MCK) reported north american pharmaceutical — antitrust legal settlements of $15.00M in Q4 2025.
- What does north american pharmaceutical — antitrust legal settlements mean?
- Financial costs incurred from legal settlements related to antitrust issues within the North American Pharmaceutical segment.